GEPEX® (exemestane) is an antineoplastic agent of the family of steroidal aromatase inhibitors. GEPEX® is indicated for the adjuvant treatment of postmenopausal women who present with invasive breast cancer in initial stages with positive estrogen receptor and after 2 to 3 years of initial adjuvant treatment with tamoxifen. It is also indicated for the treatment of advanced breast cancer in women with a natural or induced postmenopausal state whose disease has progressed after anti-estrogen therapy. Efficacy has not been demonstrated in estrogen receptor negative patients. GEPEX® is presented in blister packs of 30 and 100 tablets of 25 mg.
For further information: